Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
Rhea-AI Summary
BioArctic (Nasdaq Stockholm: BIOA B) announced that partner Eisai projects Leqembi sales of JPY 143.5 billion (about SEK 8.4 billion) for FY 2026 (April 2026–March 2027), a 63% increase year over year.
This is expected to generate roughly SEK 880 million in royalties to BioArctic. The companies are preparing joint commercialization of Leqembi for Alzheimer's disease in the Nordic region.
Positive
- Eisai projects FY 2026 Leqembi sales of JPY 143.5 billion
- Projected Leqembi sales imply 63% growth versus prior fiscal year
- BioArctic expects about SEK 880 million in Leqembi royalties FY 2026
- Planned joint Leqembi commercialization with Eisai in the Nordic region
Negative
- None.
News Market Reaction – BIOA
In the May 15 session, BIOA declined 5.64%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Earnings call invite | Positive | +5.2% | Announced timing and access details for upcoming Q1 2026 report call. |
| May 08 | Earnings and pipeline | Positive | +0.9% | Reported Q1 2026 results, strong cash and positive BGE-102 Phase 1 data. |
| May 08 | Regulatory timeline update | Positive | +0.9% | Disclosed FDA PDUFA date extension for Leqembi Iqlik to August 24, 2026. |
| May 04 | R&D Day announcement | Positive | +0.4% | Scheduled R&D Day to present BGE-102 Phase 1 data and strategy. |
| Apr 21 | Annual report release | Positive | +4.3% | Published 2025 Annual and Sustainability Report with record-high profits. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news has often been followed by modestly positive price reactions, suggesting investors have rewarded updates on strategy, pipeline and reporting cadence.
Over the last few weeks, BIOA has issued several updates, including an invitation to its Q1 2026 report on May 20, an R&D Day announcement, and publication of its 2025 Annual and Sustainability Report highlighting a breakthrough Alzheimer’s drug and record-high profits. Regulatory and pipeline updates, such as the Leqembi Iqlik PDUFA date extension, also saw positive reactions. Against this backdrop, Eisai’s Leqembi revenue projection and related royalties further build on the commercial narrative for the Alzheimer’s franchise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for clinical development, marketing authorization applications and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai, and the two companies are currently preparing for a joint commercialization in the region.
BioArctic's report for the first quarter 2026 will be published on May 20 at 08.00 a.m. CET.
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 15, 2026, at 08:30 CET.
For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08
About Leqembi® (lecanemab)
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 7 countries, including the
Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
​​​​​​​Eisai projects Leqembi® revenue to total |
View original content:https://www.prnewswire.com/news-releases/eisai-projects-leqembi-revenue-to-total-jpy-143-5-billion-for-fiscal-year-2026-april-2026--march-2027-302773354.html
SOURCE BioArctic